Brief: Mindset Pharma Enters Manufacturing Agreement With Leading CDMO To Produce Pharmaceutical Grade Batches Of Next-Generation Psilocybin Drug Candidate, Msp-1014
25/01/2022 13:23
Jan 25 (Reuters) - Mindset Pharma Inc MSET.CD :
* MINDSET PHARMA ENTERS MANUFACTURING AGREEMENT WITH LEADING
CDMO
TO PRODUCE PHARMACEUTICAL GRADE BATCHES OF NEXT-GENERATION
PSILOCYBIN DRUG CANDIDATE, MSP-1014
Source text for Eikon: ID:nGNX2kSLDQ
Further company coverage: MSET.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Mindset pharma
See all newsStifel GMP sees significant uncertainty for Reunion Neuroscience over lawsuit
Brief: Reunion Neuroscience Files Lawsuit Against Mindset Pharma
Brief: Mindset Pharma announced Exclusive Licensing Agreement For Cybin To Acquire Intellectual Property Rights For Subset Of Co's Preclinical Compounds
Brief: Mindset Pharma Receives Scientific Advice From UK Regulator Facilitating Advancement Of Phase 1 First-In-Human Clinical Trial Plan
Brief: Mindset Pharma Enters Manufacturing Agreement With Leading CDMO To Produce Pharmaceutical Grade Batches Of Next-Generation Psilocybin Drug Candidate, Msp-1014